 |
|
|
| |
High SVR24 Rates with 12 to 24 Weeks of Ritonavir-Boosted Danoprevir Plus PegIFN Alfa-2a (40KD)/RBV
in HCV Genotype 1 or 4 Patients in the DAUPHINE Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 Boston
G.T. Everson,1 C. Cooper,2 C. Hezode,3 M.L. Shiffman,4 E.M. Yoshida,5 T. Beltran-Jaramillo,6 P. Andreone,7 S. Bruno,8 P. Ferenci,9 S. Zeuzem,10 M. Brunda,11 S. Le Pogam,11 I. Nájera,11 J. Zhou,12 M.T. Navarro,13
A. Voulgari,14 N.S. Shulman,13 E.S. Yetzer13
1University of Colorado School of Medicine, Denver, CO, USA; 2University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada; 3Universite Paris XII, Hôpital Henri Mondor, Creteil, France; 4Liver Institute of Virginia, Richmond and Newport News, VA, USA; 5University of British Columbia, Vancouver, BC, Canada; 6Asesor del departamento de Inmunoanálisis, Medico especialista en Medicina Interna, Mexico; 7Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy; 8Liver Unit, Azienda Ospedaliera Fatebenefratelli e Oftalmico, Milan, Italy; 9Medical University of Vienna, Vienna, Austria; 10J.W. Goethe University Hospital, Frankfurt, Germany; 11Hoffmann-La Roche Inc, Nutley, NJ, USA; 12Roche Product Development - Asia Pacific, Shanghai, China; 13Genentech, South San Francisco, CA, USA; 14Roche Products Ltd, Welwyn, UK
|
| |
|
|
|
|
|
